Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial

被引：0
|
作者：
Rafael J. A. Cámara
Lukas Schwentner
Thomas W. P. Friedl
Miriam Deniz
Visnja Fink
Krisztian Lato
Peter Widschwendter
Brigitte Rack
Wolfgang Janni
Susanne Singer
Inga Bekes
机构：
[1] Medical Centre of the University of Mainz,Institute for Medical Biometry, Epidemiology and Informatics
[2] University Hospital Ulm,Department of Gynaecology and Obstetrics
[3] Praxis für Gynäkologie und Geburtshilfe,GYNOVA
来源：
Breast Cancer Research and Treatment | 2019年 / 175卷
关键词：
Breast neoplasms; Quality of life; Toxoids; Anthracyclines; Gemcitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：627 / 635
页数：8
相关论文
共 50 条
  • [1] Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial
    Camara, Rafael J. A.
    Schwentner, Lukas
    Friedl, Thomas W. P.
    Deniz, Miriam
    Fink, Visnja
    Lato, Krisztian
    Widschwendter, Peter
    Rack, Brigitte
    Janni, Wolfgang
    Singer, Susanne
    Bekes, Inga
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 627 - 635
  • [2] Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial
    Amelie de Gregorio
    Lothar Häberle
    Peter A. Fasching
    Volkmar Müller
    Iris Schrader
    Ralf Lorenz
    Helmut Forstbauer
    Thomas W. P. Friedl
    Emanuel Bauer
    Nikolaus de Gregorio
    Miriam Deniz
    Visnja Fink
    Inga Bekes
    Ulrich Andergassen
    Andreas Schneeweiss
    Hans Tesch
    Sven Mahner
    Sara Y. Brucker
    Jens-Uwe Blohmer
    Tanja N. Fehm
    Georg Heinrich
    Krisztian Lato
    Matthias W. Beckmann
    Brigitte Rack
    Wolfgang Janni
    [J]. Breast Cancer Research, 22
  • [3] Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
    de Gregorio, Amelie
    Haberle, Lothar
    Fasching, Peter A.
    Mueller, Volkmar
    Schrader, Iris
    Lorenz, Ralf
    Forstbauer, Helmut
    Friedl, Thomas W. P.
    Bauer, Emanuel
    de Gregorio, Nikolaus
    Deniz, Miriam
    Fink, Visnja
    Bekes, Inga
    Andergassen, Ulrich
    Schneeweiss, Andreas
    Tesch, Hans
    Mahner, Sven
    Brucker, Sara Y.
    Blohmer, Jens-Uwe
    Fehm, Tanja N.
    Heinrich, Georg
    Lato, Krisztian
    Beckmann, Matthias W.
    Rack, Brigitte
    Janni, Wolfgang
    [J]. BREAST CANCER RESEARCH, 2020, 22 (01)
  • [4] Six cycles of adjuvant anthracycline-taxane-based chemotherapy compared with eight cycles for women with breast cancer.
    Lee, Michael
    Wilson, Sheridan
    Porter, David James
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] First Efficacy Results of Capecitabine with Anthracycline- and Taxane-Based Adjuvant Therapy in High-Risk Early Breast Cancer: A Meta-Analysis
    Jiang, Yiwei
    Yin, Wenjin
    Zhou, Liheng
    Yan, Tingting
    Zhou, Qiong
    Du, Yueyao
    Shen, Zhenzhou
    Shao, Zhimin
    Lu, Jinsong
    [J]. PLOS ONE, 2012, 7 (03):
  • [6] Optimal duration of adjuvant bisphosphonate treatment for high-risk early breast cancer: Results from a SUCCESS trial
    Lu, Mingbei
    Ren, Beibei
    Rao, Lingyan
    [J]. THORACIC CANCER, 2022, 13 (03) : 519 - 520
  • [7] Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
    Huober, Jens
    von Minckwitz, Gunter
    Denkert, Carsten
    Tesch, Hans
    Weiss, Erich
    Zahm, Dirk Michael
    Belau, Antje
    Khandan, Fariba
    Hauschild, Maik
    Thomssen, Christoph
    Hoegel, Bernhard
    Darb-Esfahani, Silvia
    Mehta, Keyur
    Loibl, Sibylle
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) : 133 - 140
  • [8] Late cardiotoxicity in patients with breast cancer after taxane/anthracycline-based neoadjuvant and adjuvant chemotherapy
    Koroleva, I.
    Kopp, M. V.
    Kasulin, A. N.
    Kucheryavyy, J. A.
    Byakhov, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)
    von Minckwitz, G.
    Rezai, M.
    Fasching, P. A.
    Huober, J.
    Tesch, H.
    Bauerfeind, I.
    Hilfrich, J.
    Eidtmann, H.
    Gerber, B.
    Hanusch, C.
    Blohmer, J. U.
    Costa, S. D.
    Jackisch, C.
    Paepke, S.
    Schneeweiss, A.
    Kuemmel, S.
    Denkert, C.
    Mehta, K.
    Loibl, S.
    Untch, M.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (01) : 81 - 89
  • [10] Chemotherapy-induced amenorrhea in premenopausal breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy within the SUCCESS study
    Neugebauer, Julia Katharina
    Rack, Brigitte Kathrin
    Kupka, Markus
    Dinkel, Carina
    Jaeger, Bernadette Anna Sophia
    Ortmann, Uta
    Schneeweiss, Andreas
    Schrader, Iris
    Tesch, Hans
    Rezai, Mahdi
    Soeling, Ulrike
    Noeding, Stefanie
    Zabel, Frauke
    Sommer, Harald Leo
    Friese, Klaus
    Beckmann, Matthias W.
    Janni, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345